Policy & Regulation
Developers of Russia's Sputnik V COVID-19 vaccine state only 6,000 participants have so far received both doses
22 October 2020 -

The developers of Russia's Sputnik V COVID-19 vaccine have said that only 6,000 participants have so far received both doses of the vaccine for COVID-19 that are necessary to complete the vaccination, CNN reported on Thursday.

Alexander Gintsburg, director of the Gamaleya Institute that created the vaccine, told CNN in an exclusive interview that so far 17,000 people have received the first component of the Sputnik V vaccine.

"No side effects other than those listed in the instructions and that are characteristic of any vaccine included in the national vaccination protocols have been registered as of now," Gintsburg said.

According to Gintsburg, so far, about 40,000 doses of Sputnik V have been supplied to the general population under emergency use authorisation decree, mostly doctors, COVID-19 patients and teachers,

Gintsburg added that the Gamaleya Institute and the Russian Direct Investment Fund, which sponsored the vaccine, plan to scale up production of Sputnik V in the next month using private sector sites, with the goal of producing five million vaccines a month by next year.

CNN added that by comparison, as of 6 October 2020, the vaccine cooperation of Germany's BioNTech and US drug maker Pfizer reported to have enrolled approximately 37,000 participants in the Phase 3 trial for their vaccine candidate. Over 28,000 participants in that trial have received their second dose.